Development And Characterization Of Novel Nanoparticulate Drug Delivery Carriers For Antitubercular Drug

Abstract

Tuberculosis is a ubiquitous, highly contagious chronic granulamatous communicable bacterial infectious disease caused by Mycobacterium tuberculosis and other species of same genera. Rifabutin which is useful in the management of tuberculosis.Clinical management of tuberculosis posses serious problem because the efficacy of chemotherapy has been reduced which may be attributed to the degradation of drugs before reaching the target, the low level of cell permeability to drugs, or primary drug resistance. Other reason for the failure of chemotherapy may be the difficulty in achieving adequately high concentration at the infection site, inadequate penetration of drug into macrophages and low level in cells. These problems, which arise with conventional dosage forms of antitubercular drugs, may be overcome by designing and developing a site specific delivery of antitubercular drug using surface modified solid lipid nanoparticles. Hence in the present study, it was attempted to formulate Rifabutin in the form of solid lipid nanoparticle. Solid lipid nanoparticles of Rifabutinwere obtained by adaption of lipid dispersion method. Preformulation studies were performed to check the compatibility of drug and excepient for the preparation of formulation by DSC and no interaction was found. Solubility study, partition coefficient determination, UV analysis, HPLC study, FTIR study were also performed. After the preformulation studies Rifabutin loaded solid lipid nanoparticles and mannosylatedrifalbutin loaded solid lipid nanoparticles wereprepared and a comparison was made between drug entrapment surface morphology particle size PDI and in vitro drug release. After that in vivo studies was performed and hematological study, hepatotoxicity evaluation and fluorescence microscopy were performed. Hence it was concluded enhanced alveolar macrophase uptake and cytotoxicity studies of rifabutinloaded mannosylated solid lipid nanoparticles suggest that loading another drug will open new and exciting gateway in the management of tu